Medial EarlySign Enables Leading Israeli HMO to Identify Pre-Symptomatic Patients at High Risk for Cancer

Tuesday, February 28, 2017 Cancer News
Email Print This Page Comment bookmark
Font : A-A+

Developer of Predictive Care Engine Collaborates with Maccabi Healthcare Services to Forecast Likelihood of Colorectal Cancer in General Population

KFAR MALAL, Israel, February 28, 2017 /PRNewswire/ --

Medial EarlySign (, a developer of machine

learning tools for data driven medicine, today announced first-year results of its implementation with Maccabi Healthcare Services (MHS), for ColonFlag, a tool developed in collaboration with MHS to identify individuals with a high probability of having colorectal cancer (CRC). The predictive care engine successfully instructed Maccabi on which individuals should be contacted and tested for the disease.

Maccabi, one of Israel's leading integrated delivery networks, is feeding its members' electronic medical records (EMRs) into ColonFlag to identify the top 1% at highest risk of undiagnosed CRC. All of the members analyzed by the system were not up to date with their CRC screening. Once flagged, individuals are referred for further evaluation.

"Despite the high survival rates associated with the early detection of colorectal cancer, one third of patients eligible for screening are not being addressed," said Professor Varda Shalev, M.D., M.P.A., Director, Institute for Health Research and Innovation for Maccabi Healthcare. "Medial EarlySign's algorithms, based on machine learning, have enabled us to identify those patients at the highest risk of harboring cancer earlier and prioritize resources accordingly."

Over the first twelve months of the Maccabi implementation, ColonFlag evaluated almost 80,000 individuals, of which 690 were flagged as those at highest risk for CRC. Of the 690 patients identified, 220 colonoscopies were performed and 42% had findings, including 20 cases (10%) of cancer, and further 20 individuals who had either intermediate or high risk adenomas.

"These results with Maccabi illustrate the immense potential of implementing Medial EarlySign's technology to accurately indicate subpopulations at risk of a range of serious health conditions including cancers, metabolic disorders and chronic diseases," said Ori Geva, CEO, Medial EarlySign. "While traditional systems react to visible symptoms, our prediction-based solution enables providers to identify patients at risk of harboring or developing life threatening illnesses, for earlier intervention and treatment. Colorectal cancer is just one of several potential clinical outcomes that our game-changing platform addresses."

ColonFlag is not yet cleared by the FDA for commercial use in the USA.

About Medial EarlySign  

Medial EarlySign's advanced algorithm platform accurately detects the likelihood of disease for subpopulations using basic medical information, such as blood test results, and other EMR data. The company's predictive tools provide physicians with actionable insight, while providing insurers with effective models to flag and focus on patients at risk, helping to prioritize resources, save money and improve care.  Medial EarlySign's platform addresses numerous potential clinical outcomes, including cancers, diabetes and other life-threatening illnesses. Founded in 2009, the company is headquartered in Kfar Malal, Israel. For more information, please visit

Follow Medial EarlySign on LinkedIn: Medial EarlySign and Twitter: @MedialEarlySign

Media Contact Finn Partners for Medial EarlySign Ellie Hanson +972-2-589-2006

SOURCE Medial EarlySign


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store